Keith Ferdinand News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ATU Images/Getty Images(NEW YORK) -- For decades, doctors have encouraged patients to monitor their cholesterol levels, with studies showing that heart disease risk increases with high levels of low-density lipoprotein (LDL), also known as the “bad cholesterol,” and not enough high-density lipoprotein (HDL), also known as the “good cholesterol.” Diet, exercise and medications like statins can help people regulate their good and bad cholesterol levels. But now, doctors are recognizing the importance of a third type of cholesterol -- lipoprotein (a). Lipoprotein (a) has been increasingly...

ATU Images/Getty Images(NEW YORK) -- For decades, doctors have encouraged patients to monitor their cholesterol levels, with studies showing that heart disease risk increases with high levels of low-density lipoprotein (LDL), also known as the “bad cholesterol,” and not enough high-density lipoprotein (HDL), also known as the “good cholesterol.” Diet, exercise and medications like statins can help people regulate their good and bad cholesterol levels. But now, doctors are recognizing the importance of a third type of cholesterol -- lipoprotein (a). Lipoprotein (a) has been increasingly...

ATU Images/Getty Images(NEW YORK) -- For decades, doctors have encouraged patients to monitor their cholesterol levels, with studies showing that heart disease risk increases with high levels of low-density lipoprotein (LDL), also known as the “bad cholesterol,” and not enough high-density lipoprotein (HDL), also known as the “good cholesterol.” Diet, exercise and medications like statins can help people regulate their good and bad cholesterol levels. But now, doctors are recognizing the importance of a third type of cholesterol -- lipoprotein (a). Lipoprotein (a) has been increasingly...

You can get your vaccine from your doctor, in a local pharmacy, or at a hospital. If you have Medicaid, Medicare, or private, there is no out of pocket cost to you.

The RNA interference therapeutic targeting synthesis of angiotensinogen lowered BP in adults with mild to moderate hypertension for up to 6 months after one dose in the phase 2 KARDIA-1 study.